The U.S. FDA has granted accelerated approval to Dizal Pharmaceutical’s sunvozertinib (Zegfrovy) for treating adults with locally advanced or metastatic non-small cell lung cancer bearing EGFR exon 20 insertion mutations. This approval positions Zegfrovy as a targeted oral therapy following platinum-based chemotherapy, offering a potential improvement over existing options such as Johnson & Johnson’s Rybrevant. The approval was based on overall response rate and duration of response, with continued approval contingent on confirmatory trials.